154 related articles for article (PubMed ID: 29273212)
1. Factors contributing to variation in the use of multimodality treatment in patients with gastric cancer: A Dutch population based study.
Beck N; Busweiler LAD; Schouwenburg MG; Fiocco M; Cats A; Voncken FEM; Wijnhoven BPL; van Berge Henegouwen MI; Wouters MWJM; van Sandick JW;
Eur J Surg Oncol; 2018 Feb; 44(2):260-267. PubMed ID: 29273212
[TBL] [Abstract][Full Text] [Related]
2. Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit.
Schouwenburg MG; Busweiler LAD; Beck N; Henneman D; Amodio S; van Berge Henegouwen MI; Cats A; van Hillegersberg R; van Sandick JW; Wijnhoven BPL; Wouters MWJ; Nieuwenhuijzen GAP;
Eur J Surg Oncol; 2018 Apr; 44(4):532-538. PubMed ID: 29439836
[TBL] [Abstract][Full Text] [Related]
3. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
4. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study.
Mokadem I; Dijksterhuis WPM; van Putten M; Heuthorst L; de Vos-Geelen JM; Haj Mohammad N; Nieuwenhuijzen GAP; van Laarhoven HWM; Verhoeven RHA
Gastric Cancer; 2019 Nov; 22(6):1263-1273. PubMed ID: 30949777
[TBL] [Abstract][Full Text] [Related]
5. Trends in the use of evidence-based therapy for resectable gastric cancer.
Snyder RA; Penson DF; Ni S; Koyama T; Merchant NB
J Surg Oncol; 2014 Sep; 110(3):285-90. PubMed ID: 24891231
[TBL] [Abstract][Full Text] [Related]
6. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
[TBL] [Abstract][Full Text] [Related]
7. Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival.
van Putten M; Lemmens VEPP; van Laarhoven HWM; Pruijt HFM; Nieuwenhuijzen GAP; Verhoeven RHA
Eur J Surg Oncol; 2019 Oct; 45(10):1926-1933. PubMed ID: 30982656
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America.
Knight G; Earle CC; Cosby R; Coburn N; Youssef Y; Malthaner R; Wong RK;
Gastric Cancer; 2013 Jan; 16(1):28-40. PubMed ID: 22467061
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer.
Sun Z; Nussbaum DP; Speicher PJ; Czito BG; Tyler DS; Blazer DG
J Surg Oncol; 2015 Jul; 112(1):46-50. PubMed ID: 26179329
[TBL] [Abstract][Full Text] [Related]
10. International benchmarking in oesophageal and gastric cancer surgery.
Busweiler LAD; Jeremiasen M; Wijnhoven BPL; Lindblad M; Lundell L; van de Velde CJH; Tollenaar RAEM; Wouters MWJM; van Sandick JW; Johansson J; Dikken JL
BJS Open; 2019 Feb; 3(1):62-73. PubMed ID: 30734017
[TBL] [Abstract][Full Text] [Related]
11. Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands.
Hermans TJN; Fransen van de Putte EE; Horenblas S; Lemmens V; Aben K; van der Heijden MS; Beerepoot LV; Verhoeven RH; van Rhijn BWG
Eur J Cancer; 2016 Feb; 54():18-26. PubMed ID: 26707593
[TBL] [Abstract][Full Text] [Related]
12. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea.
Chang JS; Choi Y; Shin J; Kim KH; Keum KC; Kim HS; Koom WS; Park EC
Cancer Res Treat; 2018 Jan; 50(1):118-128. PubMed ID: 28279066
[TBL] [Abstract][Full Text] [Related]
14. Adoption of evidence-based novel therapies in the treatment of gastric cancer: A national observational study.
Mokdad AA; Ali A; Yopp AC; Polanco PM; Nassour I; Mansour JC; Choti MA; Minter RM; Wang SC; Porembka MR
Cancer; 2018 Mar; 124(6):1122-1131. PubMed ID: 29211302
[TBL] [Abstract][Full Text] [Related]
15. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: Evidence from the American College of Surgeons National Cancer Database.
Greenleaf EK; Hollenbeak CS; Wong J
Surgery; 2016 Apr; 159(4):1099-112. PubMed ID: 26704785
[TBL] [Abstract][Full Text] [Related]
16. Blast from the past: Perioperative use of the Maruyama computer program for prediction of lymph node involvement in the surgical treatment of gastric cancer following neoadjuvant chemotherapy.
Rawicz-Pruszyński K; Mielko J; Ciseł B; Skórzewska M; Pikuła A; Gęca K; Skoczylas T; Kubiatowski T; Kurylcio A; Polkowski WP
Eur J Surg Oncol; 2019 Oct; 45(10):1957-1963. PubMed ID: 31178298
[TBL] [Abstract][Full Text] [Related]
17. Treatment approach, hospital practice patterns, and receipt of multimodality therapy as measures of quality for locally advanced gastric cancer.
Portuondo JI; Tran Cao HS; da Costa WL; Sada YH; Harris AHS; Massarweh NN
J Surg Oncol; 2021 May; 123(8):1724-1735. PubMed ID: 33721353
[TBL] [Abstract][Full Text] [Related]
18. Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers?
Turgeon MK; Lee RM; Keilson JM; Ju MR; Porembka MR; Alterio RE; Kronenfeld J; Datta J; Goel N; Wang A; Lee AY; Fernandez M; Richter H; Maker AV; Maithel SK; Russell MC
J Surg Oncol; 2021 Sep; 124(4):551-559. PubMed ID: 34061369
[TBL] [Abstract][Full Text] [Related]
19. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
[TBL] [Abstract][Full Text] [Related]
20. [Exploration and thoughts on perioperative treatment of advanced gastric cancer].
Li YF; Zhou ZW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):112-117. PubMed ID: 33508915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
